
Why ESMO Asia 2026 Matters for Pharma and Biotech Teams
ESMO Asia 2026 is more than an oncology congress. It is where new clinical evidence, treatment developments and expert discussions shape the conversations that pharma and biotech teams will have with healthcare professionals across Asia.
ESMO Asia 2026 takes place from 4 to 6 December 2026 at the Suntec Singapore Convention & Exhibition Centre. For pharma, biotech and medical affairs teams in the region, it is one of the most important oncology congresses of the year.
New clinical trial data presented there will quickly shape conversations with healthcare professionals. Teams that can turn that evidence into accurate, approved content fastest will lead those conversations.
What is ESMO, and what is ESMO Asia?
ESMO is the European Society for Medical Oncology. Founded in 1975 and based in Lugano, Switzerland, it is one of the world's leading professional organisations for medical oncology. Its clinical practice guidelines are used by cancer specialists in many countries.
The ESMO Congress is its flagship annual meeting in Europe. ESMO Asia is its regional congress, focused on the cancers, patients and realities of care across Asia. This year, ESMO Asia is in Singapore, and searches for "ESMO 2026" and "ESMO Asia 2026" in Singapore are already rising sharply.
What pharma and medical affairs teams will see at ESMO Asia
ESMO Asia brings together clinical research, scientific discussions and industry insights that can influence oncology treatment and commercial strategy across the region. Key areas to watch include:
- Late-breaking clinical trial data: new results that may change how oncologists in Asia think about treatment options.
- Oncology news across tumour types: updates in areas such as cancer immunotherapy and targeted therapy.
- Expert and KOL discussions: specialists debating what the evidence means for practice in the region.
- Hundreds of research posters: often the source of the most practical subgroup and real-world data.
- Competitor and pipeline signals: what other pharma and biotech companies are presenting, and how the field is reacting.
For medical affairs, MSL and marketing teams, all of this becomes questions from healthcare professionals within days of the congress closing.
The post-congress challenge: from new data to compliant content
The hard part of ESMO Asia often starts after it ends. Teams need to move quickly from scientific information to useful, accurate and compliant content for healthcare professionals.
- Make sense of the new evidence: separate the data that matters for your therapy area from the noise.
- Create content quickly: slide decks, medical information responses, scientific summaries and field materials.
- Get it through medical, legal and regulatory (MLR) review: every claim must trace back to approved evidence.
- Reach healthcare professionals while the data is still news: before the conversation moves on.
Done manually, this can take weeks. By then, the congress moment has passed.
How Bionidi helps you move faster after ESMO Asia
Bionidi is built for pharma medical affairs and marketing teams to create content from approved medical sources, such as publications and research papers, for healthcare professionals. It helps transform scientific evidence into different multimedia formats, including videos, PowerPoint presentations and interactive content.
- Start from your approved evidence. Content is built from the sources your team has already approved.
- Create content faster. Turn new data into scientific content without starting from a blank page.
- Built for MLR review. Content is prepared with traceability to its evidence, so reviewers can check supporting sources and assess claims.
- Stay consistent. Keep messaging aligned across medical affairs and marketing.
Bionidi helps teams move from approved scientific evidence to structured medical content, making it easier to prepare materials for review and deliver relevant information to field teams.
Heading to Singapore for ESMO Asia 2026?
The Bionidi team will be attending ESMO Asia 2026 in Singapore as visitors. If you're heading to Suntec for the congress, we'd love to meet and talk about how your team turns congress data into content.
Whether you're working in Medical Affairs, scientific communications or oncology marketing, let's explore how Bionidi can support your post-congress content workflow.
Heading to Singapore for ESMO Asia? Meet us there, or write to us at [email protected] to see how Bionidi works for your therapy area.
Explore Bionidi and discover how to turn scientific evidence into medical content.